{"id":57690,"date":"2024-07-27T00:03:58","date_gmt":"2024-07-27T00:03:58","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/07\/27\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/"},"modified":"2024-07-27T00:03:58","modified_gmt":"2024-07-27T00:03:58","slug":"newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/","title":{"rendered":"NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024"},"content":{"rendered":"
\n

Company to host conference call on Monday, July 29 at 8:30 a.m. ET<\/em><\/p>\n

NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam\u201d or the \u201cCompany\u201d), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (\u201cCVD\u201d) with elevated low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced it will report topline data from the Company\u2019s Phase 3 BROOKLYN clinical trial (NCT05425745) on Monday, July 29, 2024.<\/p>\n

Conference Call and Webcast<\/u><\/strong><\/p>\n

NewAmsterdam will host a live webcast and conference call to review the topline results from BROOKLYN on Monday, July 29th<\/sup>, 2024 at 8:30 a.m. ET. To access the live webcast, participants may register here<\/a>. The live webcast will be available under the “Events\u201d section of the Investor Relations page of the NewAmsterdam website at ir.newamsterdampharma.com<\/a>.<\/p>\n

To participate via telephone, please register in advance here<\/a>. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. While not required, it is recommended that participants join the call ten minutes prior to the scheduled start. An archived replay of the webcast will be available on NewAmsterdam\u2019s website.<\/p>\n

About NewAmsterdam<\/strong><\/p>\n

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.<\/p>\n

Company Contact
<\/strong>Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com<\/a><\/p>\n

Media Contact
<\/strong>Spectrum Science on behalf of NewAmsterdam
Bryan Blatstein
P: 1-917-714-2609
bblatstein@spectrumscience.com<\/a><\/p>\n

Investor Contact
<\/strong>Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com<\/a><\/p>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Company to host conference call on Monday, July 29 at 8:30 a.m. ET NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam\u201d or the \u201cCompany\u201d), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (\u201cCVD\u201d) with elevated low-density […]\n","protected":false},"author":1,"featured_media":57691,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-57690","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"\nNewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024 - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024\" \/>\n<meta property=\"og:description\" content=\"Company to host conference call on Monday, July 29 at 8:30 a.m. ET NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) — NewAmste\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-27T00:03:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/07\/NewAmsterdam-Pharma-N-V-1-2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024\",\"datePublished\":\"2024-07-27T00:03:58+00:00\",\"dateModified\":\"2024-07-27T00:03:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/\"},\"wordCount\":393,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/\",\"name\":\"NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024 - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-07-27T00:03:58+00:00\",\"dateModified\":\"2024-07-27T00:03:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024 - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/","og_locale":"en_US","og_type":"article","og_title":"NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024","og_description":"Company to host conference call on Monday, July 29 at 8:30 a.m. ET NAARDEN, the Netherlands and MIAMI, July 26, 2024 (GLOBE NEWSWIRE) — NewAmste","og_url":"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-07-27T00:03:58+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/07\/NewAmsterdam-Pharma-N-V-1-2.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024","datePublished":"2024-07-27T00:03:58+00:00","dateModified":"2024-07-27T00:03:58+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/"},"wordCount":393,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/","url":"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/","name":"NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024 - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-07-27T00:03:58+00:00","dateModified":"2024-07-27T00:03:58+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/newamsterdam-pharma-to-announce-topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-on-monday-july-29-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/57690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=57690"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/57690\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/57691"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=57690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=57690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=57690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}